Loading...
XMADPHM
Market cap1.43bUSD
Dec 20, Last price  
78.50EUR
1D
-2.79%
1Q
64.85%
Jan 2017
141.39%
IPO
62.73%
Name

Pharma Mar SA

Chart & Performance

D1W1MN
XMAD:PHM chart
P/E
1,208.72
P/S
8.69
EPS
0.06
Div Yield, %
0.85%
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
-0.50%
Revenues
158m
-19.45%
669,000471,00076,240,00085,459,000105,260,000123,387,000153,508,000152,486,000138,229,000140,476,000148,686,000192,814,000180,943,000179,337,000162,163,00085,819,000269,961,000229,831,000196,343,000158,153,000
Net income
1m
-97.70%
1,369,00042,000-48,648,000-50,665,000-43,737,000-28,136,000-12,332,000-1,373,0006,593,00011,322,00013,115,0006,588,000-24,082,000-26,745,000-5,535,000-9,180,000137,262,00092,859,00049,356,0001,137,000
CFO
-13m
L
-67,176,000-33,034,000-56,114,000-49,158,000-35,656,000-22,666,000-21,899,000-4,282,0006,319,00016,345,00022,109,00011,101,000-8,414,000-1,459,000-16,340,000-26,137,000278,942,00025,677,00038,321,000-13,446,000
Dividend
Jun 12, 20240.65 EUR/sh
Earnings
Feb 26, 2025

Profile

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
URL
https://www.pharmamar.com/es/
IPO date
Nov 02, 2015
Employees
515
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
158,153
-19.45%
196,343
-14.57%
229,831
-14.87%
Cost of revenue
150,720
140,329
128,346
Unusual Expense (Income)
NOPBT
7,433
56,014
101,485
NOPBT Margin
4.70%
28.53%
44.16%
Operating Taxes
(4,760)
(5,566)
2,270
Tax Rate
2.24%
NOPAT
12,193
61,580
99,215
Net income
1,137
-97.70%
49,356
-46.85%
92,859
-32.35%
Dividends
(11,689)
(11,761)
(10,872)
Dividend yield
1.59%
1.01%
1.05%
Proceeds from repurchase of equity
(19,295)
7,049
(7,105)
BB yield
2.62%
-0.61%
0.69%
Debt
Debt current
14,805
14,733
14,031
Long-term debt
32,672
31,519
39,037
Deferred revenue
22,137
44,899
68,634
Other long-term liabilities
896
(284)
(293)
Net debt
(121,147)
(152,959)
(71,002)
Cash flow
Cash from operating activities
(13,446)
38,321
25,677
CAPEX
(15,956)
(8,852)
(7,803)
Cash from investing activities
(43,048)
10,878
18,472
Cash from financing activities
(32,137)
(13,370)
(27,415)
FCF
520
68,330
73,073
Balance
Cash
162,562
182,420
201,880
Long term investments
6,062
16,791
(77,810)
Excess cash
160,716
189,394
112,578
Stockholders' equity
153,251
167,544
132,338
Invested Capital
105,483
142,658
183,014
ROIC
9.83%
37.82%
51.91%
ROCE
2.87%
18.03%
34.28%
EV
Common stock shares outstanding
17,916
18,063
18,085
Price
41.08
-36.11%
64.30
12.77%
57.02
-19.69%
Market cap
735,989
-36.63%
1,161,451
12.63%
1,031,207
-20.74%
EV
614,842
1,008,492
960,205
EBITDA
13,189
61,914
107,068
EV/EBITDA
46.62
16.29
8.97
Interest
2,416
2,376
3,373
Interest/NOPBT
32.50%
4.24%
3.32%